SCHEMBL7440986

SCHEMBL7440986

Cc1cccc(CC(C(=O)O)C(=O)O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTBP2 P56545 1/20 0.51
ALDH1A1 P00352 2/20 0.50
LDHA P00338 2/20 0.50
TP53 P04637 1/20 0.50
MDM2 Q00987 1/20 0.48
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
CTSB P07858 3/20 0.47
POLB P06746 3/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTPN7 P35236 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4725412 0.87 MDM2 (0.50) CTBP2ALDH1A1TP53MDM2CTSB
SCHEMBL7381207 0.87 CYP1A2 (0.62) CTBP2PPARGPPARA
SCHEMBL14525768 0.87 PPARG (0.53) CTBP2ALDH1A1LDHATP53PPARG
SCHEMBL30738540 0.85 KDM6B (0.54) CTBP2ALDH1A1TP53PPARGPPARA
SCHEMBL19295495 0.85 CTBP2 (0.49) CTBP2PPARGPPARACTSBPOLB
SCHEMBL2165111 0.85 KDM6B (0.54) CTBP2ALDH1A1TP53PPARGPPARA
SCHEMBL4950625 0.85 KDM6B (0.54) CTBP2ALDH1A1TP53PPARGPPARA
SCHEMBL31320962 0.85 KDM6B (0.54) CTBP2ALDH1A1TP53PPARGPPARA
SCHEMBL31320968 0.85 KDM6B (0.54) CTBP2ALDH1A1TP53PPARGPPARA
SCHEMBL4469435 0.85 CTBP2 (0.49) CTBP2PPARGPPARACTSBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250027130-A1 Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-23 US disclosed
WO-2023164676-A1 METHODS TO GENERATE NOVEL ACYL-TRNA SPECIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-31 WO disclosed
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC (US) 2018-07-12 US disclosed
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2018-03-15 US disclosed
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-08-18 US disclosed
WO-2016044770-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE ABBVIE INC. (US) 2016-03-24 WO disclosed
US-4929641-A DIURETICS, ANGIOTENSIN CONVERTING ENZYMES SCHERING CORPORATION (US) 1990-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235716-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 CTBP2 2313/4885ALDH1A1 601/4885LDHA 1144/4885
US-20180193315-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, KAT2A CTBP2 2288/4885ALDH1A1 482/4885LDHA 1247/4885
US-20180071262-A1 SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE KAT2B, HDAC1, HDAC9 CTBP2 2313/4885ALDH1A1 601/4885LDHA 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.